New clinical trial aims to prevent relapse in patients with DLBCL

New clinical trial aims to prevent relapse in patients with DLBCL

(BPT) - For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that one in three will see their cancer return…

2nd Generation CAR T Shows Benefit

GLPG5101, a second-generation anti-CD19/4-1BB CAR T-cell therapy, shows high complete response rates in the treatment of high-risk indolent relapsed/refractory (r/r) non-Hodgkin lymphoma, with a notably shortened vein-to-vein time, or time from leukapheresis (the separation and collection of cells) to infusion, compared with other CAR T products. “The short vein-to-vein time of GLPG5101 eliminated the need […] The post 2nd Generation CAR T Shows…